Our Blog

Prescient Therapeutics (ASX:PTX) precision oncology medicine

28 May 2019 – Prescient Therapeutics Limited (ASX:PTX) Managing Director & CEO, Steven Yatomi-Clarke discusses the company’s development pipeline, its lead drug candidate PTX-200 and its Phase 2 trial results in breast cancer.


Source: Finance News Network

Share this post